CONTINUE TO SITE
OR WAIT 15 SECS
Neurizon Therapeutics, a clinical-stage biotech company based in Australia, has announced the development of a
South Korea-based SK Biopharm has signed a strategic Memorandum of Understanding (MoU) with AI corporation Phn
Bayer and Tsinghua University (THU) have announced the signing of the sixth phase of the collaboration agreeme
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emir
SK bioscience, a global innovative vaccine and biotech company based in South Korea, has secured a larg
A research team led by Dr Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in colla
Australia's Monash University will lead the design of a first-of-its-kind mobile CT scanner to bring critical
South Korea-based Lunit, a leading provider of artificial intelligence (AI) for cancer diagnostics and therape
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organisation (CRDMO) in Chi
Vetter, a globally operating Contract Development and Manufacturing Organisation (CDMO), recently celebrated t
Medical Advances Soar With APAC’S CLINICAL TRIAL GROWTH
It’s a truth universally acknowledged that Asia-Pacific is a hotbed for clinical trials, with multiple reports confirming that it is the only region in the world to have seen a consistent surge in clinical trial activity. The Asia Pacific clinical trials market generated a revenue of $15.91 billion in 2023 and is expected to reach a projected revenue of $25.99 billion by 2030 at a compound annual growth rate of 7.3 per cent, according to the Grand View Research report. Between 2020 and 2025, China, India, Australia, Japan, South Korea, and Singapore emerged as key pillars of Asia-Pacific’s growing clinical trial ecosystem. Together, these six countries accounted for nearly 40,000 trials (39,843 in total). We take a close look at each country’s clinical trial landscape, examining who is leading in which phases, how domestic players compare to multinational sponsors, and which therapeutic areas are seeing the most activity. We also explore the challenges of running trials across such a diverse region.
MICRO-NANO PLASTICS IN WATE
ECI
eci@informz.net https://engconf.us/conferences/civil-and-environmental-engineering/microplastics-in-water-characterization-cure-and-prevention/Davos, Switzerland
4th Targeted Radiopharmaceuticals Summit US 2025
Hanson Wade
info@hansonwade.com https://targeted-radiopharma-us.com/take-part/contact-us/Boston
